India has reached a significant milestone in cancer treatment with the development of its first indigenous CAR-T cell therapy, NexCAR19. The therapy, a result of collaborative efforts by researchers from the Indian Institute of Technology (IIT) Bombay and Tata Memorial Hospital, Mumbai, has demonstrated a 73% success rate in clinical trials, offering new hope to patients battling certain types of blood cancers.
Breakthrough in Cancer Treatment
CAR-T cell therapy, a form of immunotherapy, involves modifying a patient’s T-cells to recognize and destroy cancer cells. The therapy was tested on patients with B-cell leukemia and lymphoma, rare blood cancers that affect the bone marrow and lymphatic system. The clinical trials, conducted in two phases, revealed a 73% response rate among Indian patients, as published in The Lancet Haematology.
Cost-Effective Innovation
One of the standout features of NexCAR19 is its affordability. While similar therapies in the United States cost between ₹3-4 crore, the Indian version is priced at approximately ₹25 lakh, making it accessible to a broader population. This cost-effective approach addresses a critical gap in cancer treatment, particularly in low- and middle-income countries.
Clinical Trial Highlights
- Phase 1: Involved 14 patients with relapsed or treatment-resistant B-cell lymphoma.
- Phase 2: Expanded to 50 patients with B-cell leukemia or lymphoma, with an average age of 44 years.
- Results: Among the 51 patients analyzed, 73% responded positively to the treatment. Side effects included low white blood cell count, low platelet count, and anemia, with two treatment-related fatalities reported.
A New Era in Cancer Care
The therapy, developed over 11 years, represents a significant advancement in India’s medical research capabilities. It not only provides an effective treatment option for patients with relapsed or refractory B-cell malignancies but also sets a benchmark for future innovations in gene-modified cell therapies.
This groundbreaking achievement underscores India’s growing expertise in cutting-edge medical technologies and its commitment to making advanced treatments accessible to all.
